Evidence map›Paper›PMID 40465137›Full record

SynthesisCurrent oncology reports2025

Retroperitoneal Sarcoma (RPS): A Systematic Review.

Ilaria Caturegli, Elizabeth J Lilley, Mark Fairweather, Jiping Wang, Chandrajit P Raut

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ilaria CaturegliBrigham and Women's Hospital, Boston, MA, USA. icaturegli@bwh.harvard.edu.
Elizabeth J LilleyBrigham and Women's Hospital, Boston, MA, USA.
Mark FairweatherBrigham and Women's Hospital, Boston, MA, USA.
Jiping WangBrigham and Women's Hospital, Boston, MA, USA.
Chandrajit P RautBrigham and Women's Hospital, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retroperitoneal sarcomas (RPS) are a group of rare malignancies with many histologic types. Surgery is the hallmark of curative therapy for non-metastatic disease with the extent of resection depending on the histology. RECENT

findingsNeoadjuvant therapies have limited response and efficacy in RPS; however, the benefit, regimen, and timing depend on histology. Innovative therapeutics are emerging and may prove promising. PURPOSE OF REVIEW: This review discusses the work-up, management, and advances in the field of retroperitoneal sarcoma.

Indexed as

Retroperitoneal NeoplasmsSarcomaHumansNeoadjuvant TherapyLeiomyosarcomaLiposarcomaRadiation therapyRetroperitoneal sarcoma

Identifiers

PMID40465137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.